Whether the new prostate cancer drug ‘Erleada’ will be listed for reimbursement is gaining industry attention.

The drug pricing negotiation period for Janssen Korea’s metastatic hormone-sensitive prostate cancer (mHSPC) treatment Erleada (apalutamide) with the National Health Insurance Service is about to expire this month (March).

Erleada had passed deliberation by the NHIS Cancer Disease Deliberation Committee in February and then that of the Drug Reimbursement Evaluation Committee in December of the same year and has started the drug pricing negotiation process for its reimbursement earlier this year.

If the pricing negotiations are completed within the set period